MMAF

ArtNr	HY-15579-100mg
Hersteller	MedChem Express
CAS-Nr.	745017-94-1
Menge	100 mg
Quantity options	100 mg 10 mg 25 mg 2 mg 50 mg 5 mg
Kategorie	Reagents & Chemicals Biochemicals
Typ	Chemicals
Specific against	other
Purity	99.94
Citations	[1]Doronina SO, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem. 2006 Jan-Feb;17(1):114-24.\|[2]Lee JW, et al. EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma. Clin Cancer Res. 2010 May 1;16(9):2562-70.\|[3]Lee JJ, et al. Enzymatic prenylation and oxime ligation for the synthesis of stable and homogeneous protein-drug conjugates for targeted therapy. Angew Chem Int Ed Engl. 2015 Oct 5;54(41):12020-4.\|[4]Kim EG, et al. Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted CancerTherapeutics. J Control Release. 2018 May 10;277:48-56.\|Mol Cancer Ther. 2023 Jan 31;MCT-22-0440.\|Mol Ther Nucleic Acids. 2018 Mar 2;10:227-236.\|Patent. US20210393733A1.\|Research Square Preprint. 2023 Dec 4.\|Research Square Print. 2023 Jan 6th.\|Target Oncol. 2019 Oct;14(5):577-590.\|University of Minnesota. 2022 Sep.\|Oncol Rep. 2020 Dec 9.
Smiles	CC(C)[C@H](NC)C(N[C@H](C(N([C@@H]([C@@H](C)CC)[C@H](OC)CC(N1CCC[C@@]1([H])[C@H](OC)[C@@H](C)C(N[C@H](C(O)=O)CC2=CC=CC=C2)=O)=O)C)=O)C(C)C)=O
ECLASS 10.1	32160000
ECLASS 11.0	32160000
UNSPSC	12000000
Alias	Monomethylauristatin F
Versandbedingung	Raumtemperatur
Lieferbar
Manufacturer - Type	ADC Related
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	ADC Cytotoxin; Microtubule/Tubulin
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, protect from light, stored under nitrogen)
Molecular Weight	731.96
Product Description	MMAF (Monomethylauristatin F) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF (Monomethylauristatin F) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as vorsetuzumab mafodotin and SGN-CD19A[1][2][3].
Manufacturer - Research Area	Cancer
Solubility	DMSO: 140 mg/mL (ultrasonic)
Manufacturer - Pathway	Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage; Cytoskeleton
Isoform	Auristatin
Clinical information	No Development Reported

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkt-Datenblatt anfordern

HY-15579-100mg-safety-datasheet.pdf